A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer

We conducted an open-label single-arm phase II study by combining irinotecan (FOLFIRI) and bevacizumab (BV) plus erlotinib (ER) in 2nd-line chemotherapy for patients with metastatic colorectal cancer (mCRC). Eligible mCRC patients received 1st-line standard chemotherapy but still had progressive dis...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Medicine (Baltimore)
Asıl Yazarlar: Zhao, Zhifei, Li, Jianxiong, Ye, Rui, Wu, Xuan, Gao, Lingling, Niu, Baolong
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Wolters Kluwer Health 2017
Konular:
4500
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5627801/
https://ncbi.nlm.nih.gov/pubmed/28746175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000007182
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller